SOUTH SAN FRANCISCO, Calif., August 6, 2026
Vistagen announced positive topline results from its exploratory Phase 2 repeat-dose clinical trial evaluating fasedienol, its investigational intranasal pherine therapy for the acute treatment of Social Anxiety Disorder (SAD). The randomized, double-blind, placebo-controlled study enrolled 61 adult participants and assessed the safety, tolerability, and efficacy of administering either two 3.2 µg doses given ten minutes apart, a single 3.2 µg dose, or placebo before a public speaking challenge. The study successfully achieved its primary safety objective, with repeat dosing demonstrating a favorable safety and tolerability profile comparable to single-dose administration and no new safety concerns. Although the exploratory trial was not statistically powered for efficacy, both repeat-dose and single-dose treatment groups demonstrated numerical improvements over placebo across the primary endpoint, providing encouraging evidence to support continued clinical development and future regulatory discussions.
Clinical Outcomes Show Strong Signals in Severe Social Anxiety Patients
Beyond its safety findings, the study generated promising efficacy signals across multiple clinical assessments. Patients receiving fasedienol experienced greater reductions in Subjective Units of Distress Scale (SUDS) scores than placebo, with the most notable benefit observed in participants suffering from very severe Social Anxiety Disorder. In this prespecified subgroup, pooled fasedienol treatment demonstrated nominally statistically significant improvement, while the single-dose arm also reached nominal significance compared with placebo. Secondary analyses further supported these findings, with Clinician Global Impression of Improvement (CGI-I) and Patient Global Impression of Change (PGI-C) responder rates consistently higher among treated patients. Repeat-dose therapy produced responder rates more than twice those observed with placebo, while exploratory analyses also showed significant reductions in anticipatory anxiety immediately before public speaking, reinforcing fasedienol’s potential for rapid anxiety relief in stressful real-world situations.
Results Support FDA Discussions and Future Registration Strategy
According to Vistagen, the repeat-dose study expands the growing body of clinical evidence supporting fasedienol’s differentiated nose-to-brain neurocircuitry mechanism of action, which delivers therapeutic activity without systemic absorption or direct brain uptake. Unlike conventional anti-anxiety medications, including benzodiazepines, fasedienol has demonstrated no observed interaction with GABA-A receptors or receptors associated with drug abuse liability, suggesting the potential for a rapid-onset treatment with a favorable safety profile. Company executives stated that the consistent efficacy trends observed across Phase 2 and Phase 3 clinical programs, particularly in patients with very severe Social Anxiety Disorder, will help guide upcoming FDA discussions regarding the registrational pathway. Vistagen believes these findings strengthen the clinical rationale for advancing fasedienol toward potential regulatory approval as a novel acute treatment option.
Advertisement
Innovative Intranasal Therapy Targets Unmet Need in Social Anxiety Disorder
Social Anxiety Disorder affects more than 30 million adults in the United States and remains one of the most common psychiatric conditions, often causing debilitating fear, distress, impaired social functioning, depression, and increased suicide risk. Fasedienol represents a new class of intranasal pherine therapies designed to rapidly modulate the nasal-limbic amygdala neurocircuitry responsible for fear and anxiety without relying on systemic drug exposure. If future clinical trials confirm these encouraging findings, the therapy could provide patients with a fast-acting, non-sedating alternative that minimizes the risks of dependence, abuse, drug interactions, and cognitive impairment associated with many currently available treatments. The latest Phase 2 data further position Vistagen to continue advancing fasedienol through late-stage development while working closely with regulators to establish a potential approval pathway for this innovative neuroscience therapy.
Source:Vistagen, press release
